iShares U.S. Pharmaceuticals ETF

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

bilawalmaskin@gmail.com1 hour ago02 mins

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. Shelby Knowles | Bloomberg | Getty Images Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month’s worth of doses in a single pen. Cash-paying patients can…

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial

bilawalmaskin@gmail.com4 hours ago02 mins

Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn’t meet its key goal of showing that it wasn’t inferior to Eli Lilly’s rival drug. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide after 84 weeks,…

Stocks drop as Trump raises tariffs again, sowing confusion: Live updates

US insurer The Hartford opens first India global tech centre in Hyderabad – The Times of India

Isabel May on joining

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Inside Cola King’s Daughter Devyani Jaipuria’s Delhi Farmhouse Where Europe Meets India

How the question of Darryn Peterson’s availability is shaping Kansas’ season

iShares U.S. Pharmaceuticals ETF

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial